Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  La Marca, Antonio ^a   Grisendi, Valentina ^a   Giulini, Simone ^a   Argento, Cindy ^a   Tirelli, Alessandra ^a   Dondi, Giulia ^a   Papaleo, Enrico ^b   Volpe, Annibale ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

AFC; ART; FSH; Ovarian reserve; Starting FSH dose

Indexed keywords

ESTRADIOL; FOLLITROPIN;

ADULT; AGE; ANTRAL FOLLICLE COUNT; ARTICLE; BLOOD SAMPLING; CELL COUNT; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN CELL; INTRACYTOPLASMIC SPERM INJECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; NOMOGRAM; OOCYTE RETRIEVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSVAGINAL ECHOGRAPHY;

EID: 84873259935     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-11     Document Type: Article

References (27)

1. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. BC Fauser, K Diedrich, P Devroey, Evian Annual Reproduction Workshop Group 2007, Hum Reprod Update 2008 14 1 14 18006561
2. Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. C Alviggi, P Humaidan, D Ezcurra, Reprod Biol Endocrinol 2012 10 9 10.1186/1477-7827-10-9 22309877
3. A systematic review of tests predicting ovarian reserve and IVF outcome. FJ Broekmans, J Kwee, DJ Hendriks, BW Mol, CB Lambalk, Hum Reprod Update 2006 12 685 718 10.1093/humupd/dml034 16891297
4. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). A La Marca, G Sighinolfi, D Radi, C Argento, E Baraldi, AC Artenisio, G Stabile, A Volpe, Hum Reprod Update 2010 16 113 130 10.1093/humupd/dmp036 19793843
5. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. SM Nelson, RW Yates, R Fleming, Hum Reprod 2007 22 2414 2421 10.1093/humrep/dem204 17636277
6. The antral follicle count: practical recommendations for better standardization. FJ Broekmans, D de Ziegler, CM Howles, A Gougeon, G Trew, F Olivennes, Fertil Steril 2010 94 1044 1051 10.1016/j.fertnstert.2009.04.040 19589513
7. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. A La Marca, E Spada, G Sighinolfi, C Argento, A Tirelli, S Giulini, S Milani, A Volpe, Fertil Steril 2011 95 684 688 10.1016/j.fertnstert.2010.07.1069 20797717
8. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. SL Broer, M Dólleman, BC Opmeer, BC Fauser, BW Mol, FJ Broekmans, Hum Reprod Update 2011 17 46 54 10.1093/humupd/dmq034 20667894
9. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. DJ Hendriks, J Kwee, BW Mol, ER te Velde, FJ Broekmans, Fertil Steril 2007 87 764 775 10.1016/j.fertnstert.2006.11.006 17239869
10. Antral follicle counts are related to age at natural fertility loss and age at menopause. FJ Broekmans, MJ Faddy, G Scheffer, ER te Velde, Menopause 2004 11 607 614 10.1097/01.GME.0000123643.76105.27 15545788
11. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. SM Nelson, RW Yates, H Lyall, M Jamieson, I Traynor, M Gaudoin, P Mitchell, P Ambrose, R Fleming, Hum Reprod 2009 24 867 875 19136673
12. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. AP Yates, O Rustamov, SA Roberts, HY Lim, PW Pemberton, A Smith, LG Nardo, Hum Reprod 2011 26 2353 2362 10.1093/humrep/der182 21672928
13. Development of a nomogram based on markers of ovarian reserve for the individualization of the FSH starting dose in IVF cycles. A La Marca, E Papaleo, V Grisendi, C Argento, S Giulini, A Volpe, BJOG 2012 119 1171 1179 10.1111/j.1471-0528.2012.03412.x 22805536
14. Manipulation of human ovarian function: physiological concepts and clinical consequences. BC Fauser, AM Van Heusden, Endocr Rev 1997 18 71 106 10.1210/er.18.1.71 9034787
15. Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone. R Fleming, N Deshpande, I Traynor, RW Yates, Hum Reprod 2006 21 1436 1441 10.1093/humrep/dei499 16439501
16. A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. RF Harrison, S Jacob, H Spillane, E Mallon, B Hennelly, Fertil Steril 2001 75 23 31 10.1016/S0015-0282(00)01643-5 11163812
17. A population model for the follicular growth in women treated with follicle stimulating hormone. MO Karlsson, JR Wade, E Loumaye, A Munafo, Clin Pharmacol Ther 1997 62 665 674 10.1016/S0009-9236(97)90086-2 9433395
18. FSH Treatment Guidelines Clinical Panel Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients. CM Howles, H Saunders, V Alam, P Engrand, Curr Med Res Opin 2006 22 907 918 10.1185/030079906X104678 16709312
19. A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. B Popovic-Todorovic, A Loft, A Lindhard, S Bangsbøll, AM Andersson, AN Andersen, Hum Reprod 2003 18 781 787 10.1093/humrep/deg181 12660271
20. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. F Olivennes, CM Howles, A Borini, M Germond, G Trew, M Wikland, F Zegers-Hochschild, H Saunders, V Alam, CONSORT study group, Reprod Biomed Online 2009 18 195 204 10.1016/S1472-6483(10)60256-8 19192339
21. Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in «standard» patients treated with 150 IU/day during the first cycle. B Popovic-Todorovic, A Loft, S Ziebe, AN Andersen, Acta Obstet Gynecol Scand 2004 83 842 849 15315596
22. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. B Popovic-Todorovic, A Loft, HE Bredkjaeer, S Bangsbøll, IK Nielsen, AN Andersen, Hum Reprod 2003 18 2275 2282 10.1093/humrep/deg472 14585873
23. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. AP Ferraretti, A La Marca, BC Fauser, B Tarlatzis, G Nargund, L Gianaroli, ESHRE working group on Poor Ovarian Response Definition, Hum Reprod 2011 26 1616 1624 10.1093/humrep/der092 21505041
24. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. T Eldar-Geva, A Ben-Chetrit, IM Spitz, R Rabinowitz, E Markowitz, T Mimoni, M Gal, E Zylber-Haran, EJ Margalioth, Hum Reprod 2005 20 3178 3183 10.1093/humrep/dei203 16113044
25. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. A La Marca, S Giulini, A Tirelli, E Bertucci, T Marsella, S Xella, A Volpe, Hum Reprod 2007 22 766 771 17071823
26. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. IA van Rooij, FJ Broekmans, ER te Velde, BC Fauser, LF Bancsi, FH de Jong, AP Themmen, Hum Reprod 2002 17 3065 3071 10.1093/humrep/17.12.3065 12456604
27. Possibilities and Limits of Ovarian Reserve Testing in ART. A La Marca, C Argento, G Sighinolfi, V Grisendi, M Carbone, G D'Ippolito, AC Artenisio, G Stabile, A Volpe, Curr Pharm Biotechnol 2012 13 398 408 10.2174/ 138920112799361972 21657996